Bifunctional Mesoporous
Zirconium Phosphonates for Delivery of Nucleic Acids
- Publication date
- Publisher
Abstract
The bifunctional mesoporous zirconium phosphonates (ZrBFs)
were synthesized through surfactant-assisted co-condensation of ZrCl<sub>4</sub> with two different phosphonic acids, both 1-phosphomethylproline
(H<sub>3</sub>PMP) and 1,4-bis(phosphomethyl)piperazine (BPMP), in
a one-pot procedure. The l-proline group of H<sub>3</sub>PMP and piperazine group of BPMP in the frameworks endow ZrBFs with
pH-controllable release function and high cell penetration capability,
which was derived from the reversible protonation–deprotonation
of l-proline groups and piperazine groups on the mesoporous
walls under different pH values (pH sensitivity) as well as further
functionalization with biological modifiers via the carboxyls in l-proline groups on the outer surface (functionalizability),
respectively. ZrBFs, possessing cationic frameworks once formed, exhibit
high payload for salmon sperm DNA as model nucleic acid owing to strong
electrostatic attraction between them. On the basis of pH-sensitive
ZrBFs carriers and assisted by lag-time films coating, the time- and
pH-controlled oral colon-targeted nucleic acid delivery systems have
been developed, which can carry most of the loaded salmon sperm DNA
to the colon under dual control, time control and pH value control.
Furthermore, salmon sperm DNA can remain intact during delivery,
as evidenced by the fact that the released salmon sperm DNA in the
pH transition release experiment still retain its structural integrity
and native conformation. Also, fluorescence spectra demonstrate that
ZrBFs can be further functionalized with a cell-penetrating peptide
of octaarginine (R8) via the carboxyls in l-proline groups
of H<sub>3</sub>PMP on the outer surface using a coupling agent, which
will enhance the penetration capability of ZrBFs through biomembranes.
ZrBFs have a potential application as a new kind of carrier in oral
delivery of nucleic acids targeting the colon for gene therapy of
colon-related diseases due to their unique bifunctionality